Real-world evaluation of compliance and preference in Alzheimer’s disease treatment

Real-world evaluation of compliance and preference in Alzheimer’s disease treatment

Ming-Chyi Pai,1,2 Hany Aref,3 Nazem Bassil,4 Nagaendran Kandiah,5 Jae-Hong Lee,6 AV Srinivasan,7 Shelley diTommaso,8 Ozgur Yuksel81Division of Behavioral Neurology, Department of Neurology, 2Alzheimer’s Disease Research Center, National Cheng Kung University Hospital, College of Medicine,...

Full description

Bibliographic Details
Main Authors:	Pai MC, Aref H, Bassil N, Kandiah N, Lee JH, Srinivasan AV, diTommaso S, Yuksel O
Format:	Article
Language:	English
Published:	Dove Medical Press 2015-11-01
Series:	Clinical Interventions in Aging
Subjects:	Rivastigmine Alzheimer's disease cholinesterase inhibitors patient compliance observational study clinical trials
Online Access:	https://www.dovepress.com/real-world-evaluation-of-compliance-and-preference-in-alzheimerrsquos--peer-reviewed-article-CIA

Similar Items

Real-world evaluation of compliance and preference in Alzheimer’s disease treatment: an observational study in Taiwan 
by: Lai TH, et al.
Published: (2016-03-01)

The specific features of using a rivastigmine transdermal formulation in Alzheimer’s disease
by: Elena Evgenyevna Vasenina, et al.
Published: (2012-09-01)

Alzheimer's disease - a review of medicinal substances and their derivatives
by: Marika Więcek, et al.
Published: (2024-02-01)

A 24-Week, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of the Rivastigmine Patch in Japanese Patients with Alzheimer’s Disease
by: Yu Nakamura, et al.
Published: (2011-06-01)

New Multitarget Rivastigmine–Indole Hybrids as Potential Drug Candidates for Alzheimer’s Disease
by: Leo Bon, et al.
Published: (2024-02-01)

Effectiveness and Safety of MLC601 in the Treatment of Mild to Moderate Alzheimer's Disease: A Multicenter, Randomized Controlled Trial
by: Hossein Pakdaman, et al.
Published: (2015-03-01)

Atypical Presentation of Acetylcholinesterase Inhibitor-Induced Diarrhea in Older Adults with Cognitive Decline: An Aspect not to be Underestimated
by: Raffaele Pagliuca, et al.
Published: (2023-03-01)

A 24-Week, Randomized, Controlled Study to Evaluate the Tolerability, Safety and Efficacy of 2 Different Titration Schemes of the Rivastigmine Patch in Japanese Patients with Mild to Moderate Alzheimer's Disease
by: Yu Nakamura, et al.
Published: (2015-09-01)

Rivastigmine–Benzimidazole Hybrids as Promising Multitarget Metal-Modulating Compounds for Potential Treatment of Neurodegenerative Diseases
by: David Vicente-Zurdo, et al.
Published: (2023-05-01)

Comparison of the effects of transdermal and oral rivastigmine on cognitive function and EEG markers in patients with Alzheimer's disease
by: Davide V Moretti, et al.
Published: (2014-07-01)

Comparative study of rivastigmine and galantamine on the transgenic Drosophila model of Alzheimer's disease
by: Yasir Hasan Siddique, et al.
Published: (2022-01-01)

Electrocardiographic Effects of Cholinesterase Inhibitors in Patients with Alzheimer’s Disease
by: Ayşe ÇOLAK, et al.
Published: (2022-12-01)

The effect of cholinesterase inhibitors on sleep in the patients with Alzheimer’s disease: an observational prospective study
by: Osman Korucu, et al.
Published: (2018-01-01)

Are there links between Alzheimer’s disease and ADHD? The efficacy of acetylcholinesterase inhibitors and NMDA receptor antagonists in controlling ADHD symptoms: a systematic review
by: Ramin Abdi Dezfouli, et al.
Published: (2024-02-01)

Drug Delivery Systems as a Strategy to Improve the Efficacy of FDA-Approved Alzheimer’s Drugs
by: Débora Nunes, et al.
Published: (2022-10-01)

Visual Hallucinations Due to Rivastigmine Transdermal Patch Application in Alzheimer's Disease; The First Case Report
by: Yıldız Değirmenci, et al.
Published: (2016-12-01)

Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial: a phase 3 randomised, double-blind placebo-controlled trial of rivastigmine to prevent falls in Parkinson’s disease
by: S. Neumann, et al.
Published: (2021-10-01)

RETRACTED: QbD-based rivastigmine tartrate-loaded solid lipid nanoparticles for enhanced intranasal delivery to the brain for Alzheimer's therapeutics
by: Deepshi Arora, et al.
Published: (2022-08-01)

Medicamenteuze behandeling van de ziekte van Alzheimer. De klinische praktijk in Nederland
by: CJM Scho¨lzel-Dorenbos
Published: (2024-01-01)

Cholinesterase inhibitors for Parkinson’s disease-related visual hallucinations unresponsive to atypical antipsychotics
by: Tomasz Sobow
Published: (2007-03-01)

Butyrylcholinesterase Protein Ends in the Pathogenesis of Alzheimer’s Disease—Could <i>BCHE</i> Genotyping Be Helpful in Alzheimer’s Therapy?
by: Jacek Jasiecki, et al.
Published: (2019-10-01)

Meta-Analysis of Randomized Controlled Trials on the Efficacy and Safety of Donepezil, Galantamine, Rivastigmine, and Memantine for the Treatment of Alzheimer’s Disease
by: Dan-Dan Li, et al.
Published: (2019-05-01)

CHOLINESTERASE INHIBITORS IN THE TREATMENT OF DEMENTIA ALZHEIMER’S
by: Prameidya Primaniar S
Published: (2013-03-01)

Rivastigmine–Bambuterol Hybrids as Selective Butyrylcholinesterase Inhibitors
by: Jie Wu, et al.
Published: (2023-12-01)

In vitro and in vivo Biological Evaluation of Newly Tacrine-Selegiline Hybrids as Multi-Target Inhibitors of Cholinesterases and Monoamine Oxidases for Alzheimer’s Disease
by: Huang ST, et al.
Published: (2024-01-01)

Position Statement on Anti-Dementia Medication for Alzheimer’s Disease by Swiss Stakeholders
by: Giovanni B Frisoni, et al.
Published: (2021-08-01)

Rivastigmine: the advantages of dual inhibition of acetylcholinesterase and butyrylcholinesterase and its role in subcortical vascular dementia and Parkinson’s disease dementia
by: Kandiah N, et al.
Published: (2017-04-01)

Neuroprotection of Cholinergic Neurons with a Tau Aggregation Inhibitor and Rivastigmine in an Alzheimer’s-like Tauopathy Mouse Model
by: Maciej Zadrozny, et al.
Published: (2024-04-01)

A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer’s disease
by: Deardorff WJ, et al.
Published: (2016-10-01)

Novel Rivastigmine Derivatives as Promising Multi-Target Compounds for Potential Treatment of Alzheimer’s Disease
by: David Vicente-Zurdo, et al.
Published: (2022-06-01)

The Effect of Vascular Risk Factors on the Efficacy of Rivastigmine Patch and Capsule Treatment in Alzheimer’s Disease
by: M.R. Farlow, et al.
Published: (2011-06-01)

What is the impact of regulatory guidance and expiry of drug patents on dementia drug prescriptions in England? A trend analysis in the Clinical Practice Research Datalink
by: Venexia M. Walker, et al.
Published: (2018-05-01)

Frankincense Upregulates the FMR1 Gene and Alleviates AlCl3-Induced Memory Impairment in Rats
by: Mohammad Khalaj-Kondori, et al.
Published: (2021-02-01)

Effects of a Rivastigmine Patch on Self-Care Activities in Patients with Alzheimer's Disease plus Cerebrovascular Disease
by: Yong Kyun Kim, et al.
Published: (2014-10-01)

Design, synthesis and evaluation of genistein-polyamine conjugates as multi-functional anti-Alzheimer agents
by: Xin Zhang, et al.
Published: (2015-01-01)

Rivastigmine als ondersteuning bij het dilemma van de behandeling van hallucinaties optredend bij ziekte van Parkinson
by: jmp Rovers, et al.
Published: (2024-02-01)

Alzheimer’s Disease: Differences of Transdermal versus Oral Treatment on Caregiving Time
by: O. Riedel, et al.
Published: (2012-11-01)

The Potential Effect of Insulin on AChE and Its Interactions with Rivastigmine In Vitro
by: Tahereh Jamshidnejad-Tosaramandani, et al.
Published: (2021-11-01)

Protective effect of hydro-alcoholic extract of Salvia haematodes Wall root on cognitive functions in scopolamine-induced amnesia in rats
by: Mohammad Shawwal, et al.
Published: (2017-10-01)

Formulation and characterization of polymeric nanoparticle of Rivastigmine for effective management of Alzheimer’s disease
by: Faisal Imam, et al.
Published: (2024-05-01)